ArticleProceedings of the National Academy of Sciences of the United States of America2014
Global dissemination of a multidrug resistant Escherichia coli clone.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 327 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
327 citing papers in PubMed, 3 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- Iran's Escherichia coli AMR Landscape (2010-2025): A One Health Systematic Review and Meta-Analysis.MicrobiologyOpen · 2026Pooled it
- Meta-analysis of Pandemic Escherichia coli ST131 Plasmidome Proves Restricted Plasmid-clade Associations.Scientific reports · 2020Pooled it
- Global Extraintestinal Pathogenic Escherichia coli (ExPEC) Lineages.Clinical microbiology reviews · 2019Pooled it
- Extended spectrum beta lactamases and carbapenemase-producingOne health (Amsterdam, Netherlands) · 2026Review
- Genomic global epidemiology and evolution ofMicrobial genomics · 2026Article
- Comparative Genomic Analysis of Multidrug-Resistant Escherichia coli Across Poultry-Human-Environmental Interfaces.MicrobiologyOpen · 2026Article
- Biophysical and functional characterization of the Escherichia coli Dr fimbrial envelope reveals its importance for pathogenesis and lithogenesis.PLoS pathogens · 2026Article
- Mapping the evolutionary path towards multi-drug resistance in the pandemicMicrobial genomics · 2026Article
- A community-based One Health approach to the pandemic dynamics ofAntimicrobial agents and chemotherapy · 2026Article
- Enrichment of the high-risk ST131 clone among ciprofloxacin-resistant Escherichia coli in a single-center cohort from Turkey: a molecular surveillance study.BMC infectious diseases · 2026Article
- Comparative activity of ceftibuten combinations with avibactam, ledaborbactam, and xeruborbactam against recombinant β-lactamase-producingAntimicrobial agents and chemotherapy · 2026Article
- Antimicrobial Resistance and Comparative Genome Analysis of High-RiskMicroorganisms · 2026Article
- Yad fimbriae are triggered by host cues and enhance extraintestinal pathogenic Escherichia coli tissue colonisation during bloodstream infection.PLoS pathogens · 2026Article
- Optimization of pediatric dosing regimens for aztreonam and amoxicillin/clavulanate combination therapy against multidrug-resistant bacteria.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- In silico typing maps the natural diversity of Escherichia coli transporter-dependent capsules.Nature microbiology · 2026Article
- Camel-Associated Antimicrobial Resistance: An Overlooked One Health Interface.Veterinary sciences · 2026Review
- TheMicrobial genomics · 2026Article
- Molecular epidemiology and structural diversity of O101/O162 O-antigen variants among Escherichia coli bacteremia isolates.Scientific reports · 2026Article
- Molecular characterization of virulence and multidrug resistance inVeterinary world · 2026Article
- Exploration of the genomic diversity of third-generation cephalosporin-resistantMicrobial genomics · 2026Article
267 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 1 institution in 1 country.
Funding
Abstract
Escherichia coli sequence type 131 (ST131) is a globally disseminated, multidrug resistant (MDR) clone responsible for a high proportion of urinary tract and bloodstream infections. The rapid emergence and successful spread of E. coli ST131 is strongly associated with several factors, including resistance to fluoroquinolones, high virulence gene content, the possession of the type 1 fimbriae FimH30 allele, and the production of the CTX-M-15 extended spectrum β-lactamase (ESBL). Here, we used genome sequencing to examine the molecular epidemiology of a collection of E. coli ST131 strains isolated from six distinct geographical locations across the world spanning 2000-2011. The global phylogeny of E. coli ST131, determined from whole-genome sequence data, revealed a single lineage of E. coli ST131 distinct from other extraintestinal E. coli strains within the B2 phylogroup. Three closely related E. coli ST131 sublineages were identified, with little association to geographic origin. The majority of single-nucleotide variants associated with each of the sublineages were due to recombination in regions adjacent to mobile genetic elements (MGEs). The most prevalent sublineage of ST131 strains was characterized by fluoroquinolone resistance, and a distinct virulence factor and MGE profile. Four different variants of the CTX-M ESBL-resistance gene were identified in our ST131 strains, with acquisition of CTX-M-15 representing a defining feature of a discrete but geographically dispersed ST131 sublineage. This study confirms the global dispersal of a single E. coli ST131 clone and demonstrates the role of MGEs and recombination in the evolution of this important MDR pathogen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.